Bristol-myers Squibb Compnay

Elucida Oncology, Inc.

Other

Francis Y F Lee

Aranapakam Mudumbai Venkatesan

Gregory P Adams

Kai Ma

Geno J Germano, Jr

Thomas Courtney Gardinier, Ii

Melik Ziya Türker

Fei Wu

Feng Chen

Jagabandhu Das

Ping Chen

John Wityak

Joel C Barrish

Louis John Lombardo

Derek J Norris

Ronald W Pero

Arthur M P Doweyko

Vijay H Naringrekar

Krishnaswamy Srinivas Raghavan

Ramesh Padmanabha

Miriam K Franchini

Thomas A Haby

Hans Olov Sj&ouml;gren

Klaus Edvardsen

Gregory Paul Adams

Geno J Germano

Melik Ziya TÜRKER

Thomas Courtney Ii Gardinier

The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.

Folate receptor targeted nanoparticle drug conjugates and uses thereof

Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.

Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases

Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases

Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

Cyclic protein tyrosine kinase inhibitors

Pharmaceutical compositions containing C-21 modified epothilone derivatives, methods for their preparation and dosing regimen for administration of these epothilone compounds are provided. The compositions are stable and readily prepared for administration by dissolution in aqueous vehicles suitable for intravenous administration. A process for formulating C-21 modified epothilone derivatives for oral and parenteral administration is disclosed.

Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives

The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect. The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.

Oral administration of epothilones

A method of treating immune suppression in a warm-blooded animal bearing a tumor, by administering to the animal an amount of combretastatin A4 and/or a prodrug thereof effective to enhance immune responsiveness without causing vascular destruction. Immunotherapy treatment to inhibit or kill tumor cells includes administering to the animal an immune-response-stimulating agent such as a vaccine of tumor cells genetically modified to produce an immune-response-enhancing cytokine while counteracting tumor-induced immune suppression in the animal by administering combretastatin A4 and/or a prodrug thereof.

Use of combretastatin A4 and its prodrugs as an immune enhancing therapy

Epothilone derivatives for the treatment of refractory tumors

Treatment of refractory tumors using epothilone derivatives

Growing community of inventors

Yardley, PA, United States of America

Francis Y F Lee